Indivior Study Links Monthly Injectable Buprenorphine to Significant Cost Savings
Event summary
- A retrospective observational study published in Frontiers in Public Health found that patients adherent to Indivior's SUBLOCADE for 12 months experienced 42% lower adjusted non-MOUD medical costs compared to those adherent to other MOUD.
- SUBLOCADE-adherent patients had the lowest rates of inpatient admissions, emergency department visits, and detoxification services.
- The study estimates an average annual cost savings of $15,017 per patient for those adherent to SUBLOCADE.
- The study was conducted using commercially insured patients and overlapped with the COVID-19 pandemic, potentially influencing healthcare utilization patterns.
The big picture
The study reinforces the growing recognition of the economic burden associated with untreated opioid use disorder and highlights the potential for long-acting injectable therapies to improve patient outcomes and reduce healthcare costs. While adherence to MOUD remains a significant challenge, this data provides a compelling argument for expanding access to and reimbursement for extended-release buprenorphine treatments, potentially shifting the focus of OUD treatment from acute care to preventative, long-term management.
What we're watching
- Market Penetration
- The pace at which SUBLOCADE adoption expands within the broader MOUD market will be critical, given the study's findings on cost savings and the existing challenges of treatment continuity.
- Regulatory Scrutiny
- Further research and real-world evidence will be needed to support the long-term cost-effectiveness of SUBLOCADE and potentially influence reimbursement policies.
- Competitive Landscape
- The emergence of competing long-acting injectable buprenorphine therapies could erode Indivior’s market share and pricing power, requiring continued innovation and differentiation.
Related topics